Accessibility settings

Published on in Vol 12 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/89025, first published .
Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

Barriers and Opportunities to Include Underrepresented Population Groups in Vaccine Trials: Cross-Sectional, Observational, Online Survey Study From the VACCELERATE Research Network

Mine Durusu Tanriover   1, 2 , MD ;   Dimitrios Poulimeneas   3 , BSc, MPH, PhD ;   Grammatiki-Christina Tsopela   3 , MSc, MD ;   Ioannis Kopsidas   3 , MD, PhD ;   Christos Argyropoulos   4 , MEng, MSc, PhD ;   Romina Di Marzo   5 ;   Olena Valdenmaiier   6 , MSc ;   Stine Finne Jakobsen   6 , MSc, PhD ;   Paula Valle Simon   7, 8 , PhD ;   Antonio Javier Carcas-Sansuan   7, 8 , MD ;   Ole F Olesen   5 , PhD ;   Oliver A Cornely   9, 10, 11, 12 , MD, PhD ;   Zoi Dorothea Pana   13 , MSc, MD, PhD ;   Theoklis Zaoutis   3 , MSCE, MD, PhD ;   Murat Akova   2, 14 , MD

1 Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey

2 Vaccine Institute, Hacettepe University, Ankara, Turkey

3 Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece

4 Chemical Engineering Department, King Fahd University of Petroleum & Minerals (KFUPM), Dhahran, Saudi Arabia

5 European Vaccine Initiative (EVI), Heidelberg, Germany

6 Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

7 Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

8 Servicio Madrileño de Salud, Madrid, Spain

9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

10 Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

11 Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

12 Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

13 School of Medicine, Department of Basic & Clinical Sciences, University of Nicosia, Nicosia, Cyprus

14 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Corresponding Author:

  • Mine Durusu Tanriover, MD
  • Department of Internal Medicine
  • Faculty of Medicine
  • Hacettepe Üniversitesi Aşı Enstitüsü Sıhhiye
  • Ankara 06230
  • Turkey
  • Phone: 90 312 305 3069
  • Email: mdurusu@yahoo.com